Adverum Biotechnologies doses first Wet AMD patient in phase-1 trial
Category: #health  By Pankaj Singh  Date: 2019-06-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

Adverum Biotechnologies doses first Wet AMD patient in phase-1 trial

The California-based Adverum Biotechnologies Inc., which caters to the unmet medical requirements in rare and ocular diseases, has announced that it dosed its first wet AMD patient in the second cohort of its OPTIC phase 1 clinical trial for ADVM – 022 gene therapy. Reportedly, patients are receiving a single intravitreal injection of ADVM – 022 with a dosage of 2 x 10 ^11 vg/eye.

As per trusted sources, during the first phase of treatment, 6 patients were given ADVM – 022 at a dose of 6 x 10^11 vg/eye. In the second phase, the patients were given a dosage of 2 x 10^11 vg/eye owing to the strong preliminary anatomical response observed among patients in the first cohort. The primary endpoint of the trial is to test the safety and tolerability of the therapy at 24 weeks after giving the dosage to the patients. Each person undergoing the trial will be carefully monitored for a period of two years.

Arshad M. Khanani, M.A., M.D., trial investigator and director of clinical research department at Sierra Eye Associates, was reportedly quoted stating that ADVM – 022 has the ability to transform the prevailing treatment of neovascular AMD. A more consistent treatment can enhance long-term vision outcomes for patients in clinical practice in addition to alleviating the treatment burden, Khanani added.

For the record, ADVM – 022 uses a trademarked vector capsid (AAV.7m8) – which carries an aflibercept coding sequence – controlled by an expression cassette. It is then delivered as a sole intravitreal administration.

The existing therapy for treating wet AMD is anti-VEGF intravitreal injections. These injections work for a temporary period and need to be taken every 4-8 weeks to maintain vision gains.

Reportedly, eight foremost retinal care centers spread across the United States are anticipated to participate in the OPTIC phase 1 clinical trial of ADVM – 022.

 

Source: http://investors.adverum.com/news-releases/news-release-details/adverum-biotechnologies-doses-first-patient-second-cohort-optic



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...